Replies to post #163670 on Biotech Values

[DewDiligence]

ENTA/Medivir—I tend to think the more pills in a given [HCV] combo, the harder it is going to be to compete with GILD on price.

For all-oral HCV regimens, the cost of goods (excluding embedded royalties) will be trivial in the overall scheme of things.